Intercept Pharmaceuticals Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    Benchmark Indexes Continue to Outperform IBB and XBI

    The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.

    By Peter Neil
  • uploads///ecg electrocardiogram stethoscope
    Company & Industry Overviews

    Array BioPharma: Why Wall Street Analysts Are Positive

    Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”

    By Daniel Collins
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Part  Graph
    Company & Industry Overviews

    JPMorgan Upgrades Ophthotech: Stock Skyrockets

    Ophthotech (OPHT) rose 11.6% for the week ended June 3, 2016, and outperformed the SPDR S&P 500 ETF (SPY). It was one of the top mid-cap performers.

    By Peter Neil
  • uploads///puzzle _
    Earnings Report

    What Analysts Recommend for Array BioPharma Stock

    As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.

    By Sarah Collins
  • uploads///drug _
    Healthcare

    If You Own Intercept Stock, Should You Sell It Now?

    On Monday, Intercept Pharmaceuticals (NASDAQ:ICPT) stock lost 39.7% and closed at $46.70 with a market cap of $1.54 billion.

    By Ambrish Shah
  • uploads///human digestive system _
    Company & Industry Overviews

    Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor

    Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.

    By Margaret Patrick
  • uploads///stock _
    Company & Industry Overviews

    CymaBay Therapeutics: What Investors Should Watch For

    CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).

    By Margaret Patrick
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///medications _
    Company & Industry Overviews

    A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

    In this series, we’ll analyze three pharmaceutical companies with focused nonalcoholic steatohepatitis pipelines.

    By Kenneth Smith
  • uploads///Axovant ana reco
    Company & Industry Overviews

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”

    By Kenneth Smith
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.

    By Daniel Collins
  • uploads///RECOMMENDATIONS
    Company & Industry Overviews

    Analysts Are Bullish on Viking Therapeutics Stock

    On June 1, Viking Therapeutic had a consensus 12-month target price of $10.63, which implies a 12-month investment return potential of ~4.7%.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///ICPT_
    Company & Industry Overviews

    An In- Depth Look at Intercept Pharmaceuticals’ Ocaliva

    Intercept Pharmaceuticals is evaluating a development strategy for Ocaliva in other indications.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.

    By Kenneth Smith
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    GILD’s Positive Results from Phase 2 Trial Evaluating Selonsertib as NASH Therapy

    Gilead Sciences (GILD) is preparing to pose strong competition to other NASH players such as Allergan (AGN), Intercept Pharmaceuticals (ICPT), and Shire Pharmaceuticals (SHPG).

    By Margaret Patrick
  • uploads///NASH pipeline
    Company & Industry Overviews

    In Depth Review of Gilead Sciences’ NASH Pipeline Opportunities

    Nonalcoholic steatohepatitis (or NASH) doesn’t have any existing approved treatments on the market, but a number of companies are vying for a share of the untapped market.

    By Sarah Collins
  • uploads///NASH opportunity
    Company & Industry Overviews

    Allergan Enters the Attractive NASH Market

    Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.

    By Jillian Dabney
  • uploads///NASH pipeline
    Company & Industry Overviews

    Understanding Gilead Sciences’ NASH Pipeline

    Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.

    By Jillian Dabney
  • Company & Industry Overviews

    What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?

    The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are XBI’s Holdings’ Moving Averages Trending?

    On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Can XBI Continue the Upward Trend It Achieved in May?

    The SPDR S&P Biotech ETF (XBI) reflected the performance of SPY and rose 0.2%, continuing its upward trend. XBI had a good month in May and began June on a positive note.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Ionis’s Metabolic Segment: Phase I and Phase II Studies

    Ionis Pharmaceuticals (IONS) is developing drugs for the treatment of various types of metabolic disorders, including diabetes, obesity, and non-alcoholic steatohepatitis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals Doing with IONIS-TTR?

    In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes

    Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Myriad Genetics: Top Performer in the Biotechnology Subgroup

    Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Shire-Dyax Merger Drove Biotech Stocks

    Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    ISIS Rose 11.4%, Helped the Biotechnology Subgroup’s Performance

    ISIS Pharmaceuticals (ISIS) rose by 11.4% on October 27, 2015. The stock rose due to news of a $5 million milestone payment from GlaxoSmithKline (GSK).

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Alnylam Up 2.0% on Phase 1 Initiation of OLE Study with ALT-AT3

    Alnylam Pharmaceuticals (ALNY) rose 2.0% on news that it has initiated a Phase I open-label extension (or OLE) study with ALN-AT3 for the treatment of hemophilia and rare bleeding disorders.

    By Peter Neil
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    Analyzing Juno Therapeutics’ Performance until September 2015

    Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    ICPT and XON Put Pressure on XBI’s Biotechnology Sector

    Intrexon (XON) plummeted by 14.4% after it announced its 2Q15 results. As per the company’s press release, XON’s total revenue was $44.9 million.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.